Have to agree with Coldchain considering GSK's move on Morphosys was on a PhaseII drug for RA. How long has PYC been persuing CD40l for RA and still no proof of concept even ?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.120(9.38%) |
Mkt cap ! $816.5M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.40 | $1.30 | $446.5K | 332.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2717 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 14139 | 2 |
View Market Depth
| Last trade - 13.11pm 07/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |